Dicerna Pharmaceuticals Inc
DRNADelisted Dec 28, 2021- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001399529
Dicerna Pharmaceuticals Inc was delisted on Dec 28, 2021; its insiders filed their last Form 4 on Dec 29, 2021; 173 institutions reported holding it in 13F filings for Q3 2021, worth $1.28B in total; Maverick Capital was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dicerna Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dicerna Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hoffman Stephen J | Director | 0 | Dec 29, 2021 | 0 |
| Buchi J Kevin | Director | 0 | Dec 29, 2021 | 0 |
| Kozin Marc D | Director | 0Indirect | Dec 29, 2021 | 0 |
| Fambrough Douglas | Chief Executive Officer | 0 | Dec 29, 2021 | 0 |
| Doberstein Stephen K | Director | 0 | Dec 29, 2021 | 0 |
| Koppel Adam | Director | 0Indirect | Dec 29, 2021 | 0 |
| Brown Bob D | Chief Scientific Ofr., EVP R&D | 0 | Dec 29, 2021 | 0 |
| Weissman James B | Chief Operating Officer & EVP | 0 | Dec 29, 2021 | 0 |
| Smith Cynthia | Director | 0 | Dec 29, 2021 | 0 |
| Gray Patrick M. | Director | 0 | Dec 29, 2021 | 0 |
| Pagan Douglas W. | Chief Financial Officer | 0 | Dec 29, 2021 | 0 |
| Freed Martin I | Director | 0 | Dec 29, 2021 | 0 |
| Aradhye Shreeram | EVP & Chief Medical Officer | 0 | Dec 29, 2021 | 0 |
| Ciappenelli Robert D. | Chief Strategy Officer | 0 | Dec 29, 2021 | 0 |
| Zeng Ling | Chief Legal Officer & Sec'y | 0 | Dec 29, 2021 | 0 |
| Paglia Regina M. | Chief Human Resources Officer | 2,027 | Jul 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −24.9K | $37.94 | −$946.1K | −98.9%267 after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −21.3K | $21.06 | −$447.5K | −98.8%267 after | |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Zeng LingChief Legal Officer & Sec'y | SSale | −1.33K | $21.47 | −$28.6K | −29.3%3.22K after | |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Aradhye ShreeramEVP & Chief Medical Officer | SSale | −2.06K | $21.47 | −$44.1K | −29.3%4.97K after | |
| Aug 10, 2021 (view filing) | Aug 10 | Same day | Fambrough DouglasPresident and CEO | PPurchase | +5.00K | $22.10 | +$110.5K | +13.1%43.2K after | |
| Aug 10, 2021 (view filing) | Aug 10 | Same day | Kozin Marc DDirector | PPurchase | +3.00K | $23.66 | +$71.0K | +90.0%6.33K after | |
| Aug 3, 2021 (view filing) | Aug 2 | 1 day | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −8.31K | $37.38 | −$310.7K | −27.9%21.5K after | |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Weissman James BChief Operating Officer & EVP | SSale | −30.0K | $39.09 | −$1.17M | −65.2%16.0K after | |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Brown Bob DChief Scientific Ofr., EVP R&D | SSale | −8.31K | $37.37 | −$310.6K | −27.9%21.5K after | 2 lots |